<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="31077">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02702141</url>
  </required_header>
  <id_info>
    <org_study_id>SGN19B-001</org_study_id>
    <nct_id>NCT02702141</nct_id>
  </id_info>
  <brief_title>A Safety Study of SGN-CD19B in Patients With B-cell Non-Hodgkin Lymphoma</brief_title>
  <official_title>A Phase 1, Open-label, Dose-escalation Study of SGN-CD19B in Patients With Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seattle Genetics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seattle Genetics, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will examine the safety profile of SGN-CD19B administered as a single agent. The
      main purpose of the study is to estimate the highest dose that does not cause unacceptable
      side effects of SGN-CD19B in patients with relapsed or refractory aggressive B-cell
      non-Hodgkin lymphoma (NHL) subtypes of diffuse large B-cell lymphoma (DLBCL) and Grade 3
      follicular lymphoma (FL3). Additionally, the pharmacokinetic profile and antitumor activity
      of SGN-CD19B will be assessed.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      SGN-CD19B will be given to patients at increasing doses every 28 days (or on an alternative
      dosing schedule of every 42 days).

      Individual expansion cohorts of up to approximately 20 patients will be opened at dose
      levels selected by the Safety Monitoring Committee based on the aggregate known safety and
      activity data to further define the safety and antitumor activity in refractory and relapsed
      disease subgroups.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2016</start_date>
  <completion_date type="Anticipated">March 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>Through 1 month following last dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of laboratory abnormalities</measure>
    <time_frame>Through 1 month following last dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Blood concentrations of SGN-CD19B</measure>
    <time_frame>Through 3 weeks after dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of antitherapeutic antibodies</measure>
    <time_frame>Through 1 month following last dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate</measure>
    <time_frame>Through 1 month following last dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of response</measure>
    <time_frame>Through 1 month following last dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>Up to approximately 3 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Non-Hodgkin Lymphoma</condition>
  <condition>DLBCL</condition>
  <condition>Diffuse Large B-cell Lymphoma</condition>
  <condition>Grade 3 Follicular Lymphoma</condition>
  <arm_group>
    <arm_group_label>SGN-CD19B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SGN-CD19B</intervention_name>
    <description>Given intravenously Day 1 of 28-day or 42-day cycles</description>
    <arm_group_label>SGN-CD19B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Relapsed, refractory, or progressive disease following at least 2 prior systemic
             therapies

          -  Measurable disease

          -  Eastern Cooperative Oncology Group status of 0 or 1

          -  Adequate baseline renal and hepatic function

        Exclusion Criteria:

          -  Prior treatment with CD19 directed agents unless CD19 expression is confirmed after
             completion of CD19-directed treatment

          -  Known HIV, active hepatitis B or active hepatitis C infection

          -  Prior allogeneic stem cell transplant

          -  Inadequate lung function

          -  Anticancer treatment within 4 weeks of study drug or 2 weeks if patient experienced
             disease progression on prior treatment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Corinna Palanca-Wessels, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Seattle Genetics, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Seattle Genetics Trial Information Support</last_name>
    <phone>866-333-7436</phone>
    <email>clinicaltrials@seagen.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Traci McArdle</last_name>
      <phone>205-975-0960</phone>
      <email>mcardlet@uab.edu</email>
    </contact>
    <investigator>
      <last_name>Andres Forero-Torres</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>City of Hope National Medical Center</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010-3000</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brianna Phye</last_name>
      <phone>626-218-0478</phone>
      <email>brbrophy@coh.org</email>
    </contact>
    <investigator>
      <last_name>Lihua Elizabeth Budde</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cardinal Bernardin Cancer Center / Loyola University Medical Center</name>
      <address>
        <city>Maywood</city>
        <state>Illinois</state>
        <zip>60153</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sally Quinn</last_name>
      <phone>708-327-2027</phone>
      <email>squinn@luc.edu</email>
    </contact>
    <investigator>
      <last_name>Patrick Stiff</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Samantha Huang</last_name>
      <phone>617-667-1903</phone>
      <email>Shuang6@bidmc.harvard.edu</email>
    </contact>
    <contact_backup>
      <last_name>Eric Jacobsen</last_name>
      <phone>617-632-6633</phone>
      <email>eric_jacobsen@dfci.harvard.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Robin Joyce</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Rocchio</last_name>
      <phone>617-632-5221</phone>
      <email>MichaelJ_Rocchio@DFCI.HARVARD.EDU</email>
    </contact>
    <contact_backup>
      <last_name>Eric Jacobsen</last_name>
      <phone>617-632-6633</phone>
      <email>eric_jacobsen@dfci.harvard.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Eric Jacobsen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hackensack University Medical Center</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christie Rice</last_name>
      <phone>551-996-5598</phone>
      <email>Christie.Rice@HackensackMeridian.org</email>
    </contact>
    <investigator>
      <last_name>Tatyana Feldman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>New York University (NYU) Cancer Institute</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ankeeta Joshi</last_name>
      <phone>212-263-4415</phone>
      <email>Ankeeta.Saran@nyumc.org</email>
    </contact>
    <investigator>
      <last_name>Catherine Diefenbach</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amanda Courtien</last_name>
      <phone>646-449-1304</phone>
      <email>courtiea@mskcc.org</email>
    </contact>
    <investigator>
      <last_name>Craig Moskowitz</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina/Hollings Cancer Center</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shanta Salzer</last_name>
      <phone>843-792-1463</phone>
      <email>salzers@musc.edu</email>
    </contact>
    <investigator>
      <last_name>Robert Stuart</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Derek Chang</last_name>
      <phone>801-213-5652</phone>
      <email>derek.chang@hci.utah.edu</email>
    </contact>
    <investigator>
      <last_name>Ahmad Halwani</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Seattle Cancer Care Alliance / University of Washington</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109-1023</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shahaan Smith</last_name>
      <phone>206-288-6448</phone>
      <email>sjsmith@seattlecca.org</email>
    </contact>
    <investigator>
      <last_name>Stephen Smith</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Carbone Cancer Center / University of Wisconsin</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>United States</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Linda Westrick</last_name>
      <phone>608-263-1836</phone>
      <email>westrick@uwcarbone.wisc.edu</email>
    </contact>
    <investigator>
      <last_name>Vaishalee Kenkre</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 30, 2017</lastchanged_date>
  <firstreceived_date>February 25, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Non-hodgkin lymphoma</keyword>
  <keyword>Antibody-drug conjugate</keyword>
  <keyword>CD19</keyword>
  <keyword>Diffuse large B-cell lymphoma</keyword>
  <keyword>DLBCL</keyword>
  <keyword>Grade 3 follicular lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Follicular</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
    <mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
